SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech failure, 2002
An SI Board Since January 2002
Posts SubjectMarks Bans
130 20 0
Emcee:  Miljenko Zuanic Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
80MZ: THere are dosage issues, I think, but I have to say this outcome was a surprMao II-6/9/2002
79Biogen vs. Serono Bad for one, good for the other? When Biogen introduced AVENEAlfred W. Post-6/9/2002
78<I find these success/failure boards very useful, and appreciate your postingElmer-6/8/2002
77Thanks, I find these success/failure boards very useful, and appreciate your posaknahow-6/8/2002
76<<Do you really want to include slow downs in sales of one drug due to comMiljenko Zuanic-6/8/2002
75Autoreceptor activation and micro doses.Miljenko Zuanic-6/8/2002
74Just a question. Do you really want to include slow downs in sales of one drug aknahow-6/8/2002
73"Pagoclone problems surfaced three years ago" -- what problems are youMao II-6/8/2002
72Today both disappointments were predictable, in one hand. Pagoclone problems surMiljenko Zuanic-6/7/2002
71This does not sound good for many FT inhibitors, now in clinic. Also, give choicMiljenko Zuanic-5/20/2002
70[farnesyl transferase inhibitor in GI cancer] Johnson & Johnson Pharmaceutikeokalani'nui-5/20/2002
69<< Remember, virtually everyone was going "huh?" when Bristol KnMiljenko Zuanic-5/20/2002
68Agree with everything you said. I have looked at IMCL results and trial design scaram(o)uche-5/20/2002
67Failure is for H&N cancer (PII and PIII), where companies (IMCL and B-k-S) wMiljenko Zuanic-5/19/2002
66Single agent results are good. 10% objective responses. Ironic, it may be bettscaram(o)uche-5/19/2002
65another asco faillure ORLANDO, Fla., May 19 /PRNewswire-FirstCall/ -- Proteidalroi-5/19/2002
64You were right when you warned us about this one. New Trial Data Is Another DisElmer-5/19/2002
63Anti-clot drug powerless during some heart attacks By Gene Emery BOSTON, May Elmer-5/15/2002
62Emisphere Technologies Reports Results From Phase III Oral Heparin PROTECT Trialnigel bates-5/14/2002
61Phase 2B ABX-IL8 Study in Psoriasis Does Not Meet Primary Efficacy Endpoint FREnigel bates-5/14/2002
60Thursday May 9, 9:07 pm Eastern Time Press Release SOURCE: Neose Technologies, IMiljenko Zuanic-5/9/2002
59Nigel IntraBiotics Announces Topline Results of Phase III Clinical Trial of Isedalroi-5/6/2002
58IntraBiotics Announces Topline Results of Phase III Clinical Trial of Iseganan Inigel bates-5/6/2002
57Ribozyme shares crumble after disappointing data (RZYM) By Michael Baron Ribozymkeokalani'nui-4/30/2002
56icos preopening now at 28 INDIANAPOLIS, April 30 (Reuters) - Drugmaker Eli Lildalroi-4/30/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News